Objective To investigate the clinical significance of related inflammatory biomarkers on chronic obstructive pulmonary disease (COPD) associated mortality,in order to provide the basis for clinical screening of high risk patients.Methods One thousand five hundred cases of outpatients and inpatients from Feb.2012 to Mar.2013 were selected as our subjects.All patients were conducted 15-27 months followup.According to patient outcome,they were divided into survival(1346 cases) and death groups (154 cases).The clinical data,pulmonary function,level of respiratory difficulty and inflammatory biomarker levels were recorded.Results The average age of the death group was (65.3 ± 12.2) years old,significantly higher than that of the survival group ((60.2 ± 11.5) years old,and the difference was significant (t =5.180,P ＜ 0.01).Body mass index(BMI) in death group was (19.8 ±5.4) kg/m2,significantly lower than that of the survival group(23.2 ± 5.6) kg/m2 and the difference was significant (t =7.373,P ＜ 0.01).There was no statistical difference between the two groups in terms of gender (P ＞ 0.05).The levels of 1 s forced expiratory volume (FEV1),FEV1/forced vital capacity (FVC),the British Medical Research Council dyspnea scale (MMRC) rating in death group were (1.1 ± 0.4) L,(40.8 ± 8.2) ％ and (2.8 ± 1.3),significantly lower than those of the survival group((1.5 ±0.5) L,(46.3 ± 11.2) ％,(2.1 ± 1.2))..FEV1 and FEV1/FVC of death group were significantly lower than those of the survival group,while the MMRC significantly higher,and the differences were significant (t =9.582,5.914,6.797,P ＜ 0.01).The levels of C-reactive protein(CRP),interleukin-6(IL-6),IL-8,tumor necrosis factor-α (TNF-α),neutrophil levels in death group were (4.8 ± 1.2)mg/L,(154.4 ± 28.6) ng/L,(398.8 ± 86.3) ng/L,(942.6 ± 212.8) ng/L,(6.0 ± 2.8) × 109/L,significantly higher than those of the survival group ((3.4 ± 1.1) mg/L,(112.8 ±23.6) ng/L,(332.7 ± 76.3) ng/L,(1 482.8 ± 223.6) ng/L,(5.1 ± 1.5) × 109/L),and the differences were statistically significant (t =14.818,20.242,10.041,29.684,6.299,P＜0.01).Conclusion Inflammatory biomarkers including CRP,IL-6,IL-8,TNF-α and neutrophils are the risk factors of death in patients with COPD.Then clinical attention should be paid to the patients with inflammatory biomarkers for monitoring physical level,in order to guide the clinical screening for high-risk cases,timely take corresponding measures and improve the prognosis.

Japan,one of the countries near China,has obtained great success in medical education through a long time exploration.Professor of R.Harsha Rao from America concluded the drawbacks in the early medical education in Japan,then proposed corresponding blueprint including reforming education systems,breaking the limitation in subjects and establishing comprehensive education system.Japanese medical education has been well promoted,the experience can be used in our country's medical education reforms.

OBJECTIVE:To observe clinical efficacy and ADR of domestic recombinant human interleukin-11(Ⅰ)(rhIL-11 (Ⅰ))in the treatment of thrombocytopenia in patients with malignant tumor. METHODS:In self-controlled trial,50 malignant tumor patients with thrombocytopenia induced by radiotherapy and chemotherapy were injected with 25 ?g?kg-1?d-1 rhIL-11(Ⅰ) subcutaneously. Drug withdrawal was conducted after consecutive 10 days injection or platelet count being higher than 300?109?L-1. RESULTS:The minimum mean value of platelet were(56.53?27.11)?109?L-1 after radiotherapy and chemotherapy and(126.73? 57.58)?109?L-1 after rhIL-11(Ⅰ)treatment(P

This study was conducted under the background of the internationalization of traditional Chinese medicine (TCM) terminology. Current TCM symptom terminology related to sweat was taken as basis in the extended study. The ICD classification of multiple axis and hierarchical level was used as guidance thought. This paper proposed the principle of detailed classification of TCM sweat symptoms and finally made classification rules for TCM sweatsymptoms. This study has promoted the development of TCM terminology standardization.

Objective:To explore the anticoagulant strategies during perioperative period for the patients with long-term anticoagu-lation therapy to show the important role of clinical pharmacist in drug treatment. Methods:The anticoagulant regimen during the peri-operative period participated by clinical pharmacists for one patient with long-term use of warfarin was reviewed, and combined with the related literatures, the drug choice, the administration time, dosage and treatment course were analyzed. Results: The clinical phar-macists could optimize the anticoagulant regimen by using the pharmacokinetic knowledge to decrease the risk of hemorrhage and embol-ism to the largest extent. Conclusion:During the perioperative period, warfarin should be withdrawn at least 5 days before the opera-tion, and the international normalize ratio ( INR) should be monitored. After the operation and no further bleeding, low molecular weight heparin combined with warfarin can be used in 12h, and INR should be monitored. Low molecular weight heparin can be with-drawn till the standard is reached. If the patient undergoes operation for many times, low molecular weight heparin is suggested to be used for anticoagulation during the whole operation period.

OBJECTIVE To study on the clinical features and treatment method for fungemia.METHODS The clinical features,therapy and outcome of 7 patients with fungemia which happened from 1999 to 2009 were retrospectively reviewed.RESULTS The main underlying conditions were : malignant disease in 7 patients(100%).In this group the risk factors for fungemia included:prior antimicrobial therapy(86%),steroids chemotherapy(57%).Fungal species isolated from 7 patients were: c.albicans(5),c.tropicalis(2).The overall mortality of fungemia was 86%.CONCLUSIONS In this study,the most frequent infectious agents were Candida albicans and non albicans Candida specis.Experience therapy should be begun earlier.Higher dose of fluconazole may be recommended in clinical usage.

Objective To study Curative efficacy of Oryzanol combine with Dingkundan in treatment of perimenopausal period and its effects on endocrine improvement.Methods 90 patients of perimenopausal period who received therapy from March 2014 to March 2015 in our hospital were selected as research objects.According to draw method divided into the experimental group(n=45)and the control group(n=45).Two groups of patients were psychological support.The control group was treated with Oryzanol, each 10 mg, 3 times a day.while the experimental group was on the control group, treated with Dingkundan, 1 pills each time, 2 times a day, in the morning and evening.Then Serum estradiol(E2), Follicle stimulating hormone(FSH), Luteinizing hormone(LH)level, upset hot sweating, insomnia, irritability, hung up improve time, Kupperman score, clinical efficacy of two groups were compared.Results The E2 level in experimental group was significantly higher than the control group[(72.51±5.30)pg/mL vs.(66.80±4.75)pg/mL](P<0.05), FSH、LH level was significantly lower than the control group[(21.36±1.05)mIU/ml vs.(26.09±1.89)mIU/mL,(24.34±1.01)mIU/mL vs.(20.61±1.50)mIU/mL](P<0.05);upset hot sweating, insomnia, irritability, hung up improve time was significantly lower than the control group[(11.21±2.35)d vs.(20.05±5.07)d,(12.78±2.09)d vs.(18.32±4.13)d,(11.30±2.10)d vs.(20.16±5.02)d,(10.20±2.76)d vs.(16.58±4.03)d](P<0.05);Kupperman score was significantly lower than the control group[(4.32±1.09)score vs.(12.76±3.16)score](P<0.05);total effective rate was significantly higher than the control group[93.33%(42/45)vs.75.67%(34/45)](P<0.05).Conclusion Oryzanol combine with Dingkundan is well for perimenopausal period,which can significantly improve endocrine disorders, promote its balance, improve estrogen.

Objective To study the effect of inhibition of human lung carcinoma-associated antigen gene(ALT04-AG) expression on the growth characteristic and associated gene expression of human lung carcinoma cells(L78).Methods L78 cells were transfected with recombinant plasmid vector expressing(ALT04-AG) antisense RNA mediated by liposome reagent,and treated with DFMO respectively. The growth characteristics were studied by MTT,FCM analysis.The associated gene expression was detected by immunocytochemical staining,Northern blot and gene chip analysis.Results The recombinant plasmid expressing ALT04-AG antisense RNA pALT04-AG as constructed.It was shown that the down-regulation of ALT04-AG gene expression was observed not only in pALT04-AG as transfected L78 cells,but also in DFMO-treated L78 cells,which resulted in growth inhibition of these cells.Gene chip analysis indicated that inhibition of(ALT04AG) gene expression by ALT04-AG antisense RNA regulated some proliferation associated gene expression,while inhibition of polyamine biosynthesis by DFMO regulated proliferation associated genes and also some apoptosis associated genes.Conclusion It is suggested that human lung carcinoma associated antigen gene ALT04-AG plays an essential role in maintaining malignant phenotype of cancer cells.

Objective This study compared the efficacy and safety of atorvastatin and simvastatin treatment for 8 weeks in hypercholesterolemic Chinese adults.Methods This randomized,open-lable,single center study enrolled the patients with LDL-C≥4.14mmol/L(1.6 g/L) but

Weight increasing would happen with the control of glucose in diabetic patients,whether the application of insulin or that of oral medication.Long-term and effective weight control should be done in order to lower the mortality rate.A large number of studies have shown that the mortality rate has increased along with weight gain,especially death caused by cardiovascular disease.The following measures can be used:(1)Rational target should be formulated.It would be the best that weight decrease 0.5~1.0 kg every week.(2)Diet should be controlled.Low-calorie,high protein,low-fat diet can be used.(3)Exercise therapy:Aerobic exercise will be recommended.(4)Drug intervention treatment:Metformin or Thiazolidinediones drugs can be use,Sibutramine or Orlistat can be used in the patients with serious obesity.